154 related articles for article (PubMed ID: 28178752)
21. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade.
Baker K; Lachapelle J; Zlobec I; Bismar TA; Terracciano L; Foulkes WD
Histopathology; 2011 Jun; 58(7):1107-16. PubMed ID: 21707712
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma.
Kwon SY; Bae YK; Gu MJ; Choi JE; Kang SH; Lee SJ; Kim A; Jung HR; Kang SH; Oh HK; Park JY
Histopathology; 2014 Apr; 64(5):647-59. PubMed ID: 24117859
[TBL] [Abstract][Full Text] [Related]
25. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
26. CD9 expression indicates a poor outcome in acute lymphoblastic leukemia.
Liang P; Miao M; Liu Z; Wang H; Jiang W; Ma S; Li C; Hu R
Cancer Biomark; 2018; 21(4):781-786. PubMed ID: 29286918
[TBL] [Abstract][Full Text] [Related]
27. Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer.
Mulligan AM; Pinnaduwage D; Tchatchou S; Bull SB; Andrulis IL
Cancer Immunol Res; 2016 Jan; 4(1):41-8. PubMed ID: 26546451
[TBL] [Abstract][Full Text] [Related]
28. Expression of E26 transformation specific-1 (ETS-1) in tumour-infiltrating lymphocytes (TILs) is adverse prognostic factor in invasive breast cancer.
Puzovic V; Jakic-Razumovic J
Breast Dis; 2021; 40(1):25-31. PubMed ID: 33459689
[TBL] [Abstract][Full Text] [Related]
29. CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.
Sim SH; Bae CD; Kwon Y; Hwang HL; Poojan S; Hong HI; Kim K; Kang SH; Kim HS; Um TH; Park IH; Lee KS; Jung SY; Lee S; Kang HS; Lee ES; Kim MK; Hong KM; Ro J
PLoS One; 2017; 12(8):e0182107. PubMed ID: 28771517
[TBL] [Abstract][Full Text] [Related]
30. High nuclear MSK1 is associated with longer survival in breast cancer patients.
Pu X; Storr SJ; Ahmad NS; Rakha EA; Green AR; Ellis IO; Martin SG
J Cancer Res Clin Oncol; 2018 Mar; 144(3):509-517. PubMed ID: 29327245
[TBL] [Abstract][Full Text] [Related]
31. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
32. Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.
Zhang Y; Jiang C; Li H; Lv F; Li X; Qian X; Fu L; Xu B; Guo X
Int J Clin Exp Pathol; 2015; 8(1):751-7. PubMed ID: 25755770
[TBL] [Abstract][Full Text] [Related]
33. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
[TBL] [Abstract][Full Text] [Related]
34. Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers.
Miyamoto S; Maruyama A; Okugawa K; Akazawa K; Baba H; Maehara Y; Mekada E
Cancer; 2001 Aug; 92(3):542-8. PubMed ID: 11505398
[TBL] [Abstract][Full Text] [Related]
35. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
[TBL] [Abstract][Full Text] [Related]
36. Expression of p16 and pRB in invasive breast cancer.
Shin E; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer.
Rajc J; Gugić D; Fröhlich I; Marjanović K; Dumenčić B
Pathol Res Pract; 2017 Sep; 213(9):1102-1108. PubMed ID: 28778498
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
39. Differential expression of immune-related markers in breast cancer by molecular phenotypes.
Choi J; Kim DH; Jung WH; Koo JS
Breast Cancer Res Treat; 2013 Jan; 137(2):417-29. PubMed ID: 23242618
[TBL] [Abstract][Full Text] [Related]
40. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
Habashy HO; Rakha EA; Ellis IO; Powe DG
Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
